Bruker Co. (NASDAQ:BRKR) Receives $70.50 Consensus Price Target from Brokerages

Shares of Bruker Co. (NASDAQ:BRKR - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eleven brokerages that are covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $66.50.

A number of equities research analysts recently commented on the company. Stifel Nicolaus lowered their price target on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research report on Friday, February 14th. Barclays lowered their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Thursday. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Citigroup decreased their price objective on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research note on Monday. Finally, Bank of America boosted their target price on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, December 13th.

Bruker Stock Up 1.8 %

Shares of Bruker stock traded up $0.69 during trading hours on Monday, reaching $38.76. The company's stock had a trading volume of 3,139,890 shares, compared to its average volume of 1,467,986. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. The stock's fifty day simple moving average is $46.16 and its two-hundred day simple moving average is $54.75. The company has a market capitalization of $5.88 billion, a P/E ratio of 51.00, a P/E/G ratio of 2.16 and a beta of 1.18. Bruker has a one year low of $34.10 and a one year high of $90.03.

Remove Ads

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. On average, research analysts forecast that Bruker will post 2.69 earnings per share for the current year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.52%. Bruker's payout ratio is 26.32%.

Institutional Trading of Bruker

A number of large investors have recently bought and sold shares of BRKR. London Co. of Virginia grew its stake in shares of Bruker by 78.4% during the 4th quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock worth $245,820,000 after acquiring an additional 1,843,294 shares during the period. Sculptor Capital LP boosted its position in Bruker by 484.1% during the fourth quarter. Sculptor Capital LP now owns 1,714,015 shares of the medical research company's stock worth $100,476,000 after purchasing an additional 1,420,569 shares during the period. FIL Ltd boosted its position in Bruker by 262.3% during the fourth quarter. FIL Ltd now owns 1,961,416 shares of the medical research company's stock worth $114,978,000 after purchasing an additional 1,420,102 shares during the period. Steadfast Capital Management LP bought a new stake in shares of Bruker in the fourth quarter valued at approximately $63,997,000. Finally, Norges Bank purchased a new stake in shares of Bruker during the 4th quarter valued at approximately $63,378,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.